Roskilde, March 13, 2025
Sonion Health, a portfolio business of Sonion, is dedicated to transforming the diagnosis and management of hypertension through innovative optical biosensing technology and artificial intelligence, allowing for accurate cuffless blood pressure monitoring. Over the years, Sonion’s scientists and engineers, recognized for their expertise in advanced components and AI solutions, have developed this cutting-edge technology. Hypertension, often termed the “Silent Killer,” is a major health concern affecting approximately 120 million adults in the U.S., with nearly half going undiagnosed. Globally, this figure rises to 1.3 billion. The U.S. market represents a $18 billion opportunity, bolstered by an established reimbursement framework.
“Our goal is to redefine how hypertension is diagnosed and managed, and we are excited to welcome Jim Fidacaro, to lead this initiative,” said Christian Nielsen, President and CEO of Sonion. Jim is an experienced executive in the medical device industry, thriving at the intersection of digital health, medical devices, and AI-driven healthcare innovations. His impressive career includes key executive positions in Fortune 500 companies, such as Philips Healthcare and Mindray, as well as in medical device startups. Jim has effectively driven market expansion, commercialization efforts, fundraising initiatives, and strategic partnerships that have shaped the future of healthcare. “I am honoured to accept this position and look forward to leading this new venture, making a lasting impact on healthcare and improving lives,” said Jim Fidacaro. Jim started on February 17, 2025, will report to Christian Nielsen and the Board, and is based in the United States, overseeing the company’s expansion.